Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Royalty Pharma PLC banner

Royalty Pharma PLC
NASDAQ:RPRX

Watchlist Manager
Royalty Pharma PLC Logo
Royalty Pharma PLC
NASDAQ:RPRX
Watchlist
Price: 58.23 USD -0.1% Market Closed
Market Cap: $33.5B
Write Note Create Alert Ask AI

Wall St Price Targets

RPRX Price Forecast
Based on 11 analysts

+15% Upside
from $58.23 today

RPRX Analyst Rating
Based on 8 analysts

Strong buy
4 50%
Buy
2 25%
Hold
2 25%
Sell
0 0%
Strong sell
0 0%
Royalty Pharma PLC Competitors:
Price Targets

Revenue
Forecast

4% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
-16%
Average Miss
4% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
-16%
Average Miss

Over the last 7 years, the compound annual growth rate for Revenue has been 4%. The projected CAGR for the next 3 years is 18%.

What are analyst estimates?

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

What are analyst estimates?

Operating Income
Forecast

2% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-37%
Average Miss
2% / Year
Past Growth
12% / Year
Estimated Growth
Estimates Accuracy
-37%
Average Miss

Over the last 7 years, the compound annual growth rate for Operating Income has been 2%. The projected CAGR for the next 8 years is 12%.

What are analyst estimates?

Pre-Tax Income
Forecast

-2% / Year
Past Growth
38% / Year
Estimated Growth
Estimates Accuracy
-34%
Average Miss
-2% / Year
Past Growth
38% / Year
Estimated Growth
Estimates Accuracy
-34%
Average Miss

Over the last 7 years, the compound annual growth rate for Pre-Tax Income has been -2%. The projected CAGR for the next 3 years is 38%.

What are analyst estimates?

Net Income
Forecast

-8% / Year
Past Growth
64% / Year
Estimated Growth
Estimates Accuracy
-66%
Average Miss
-8% / Year
Past Growth
64% / Year
Estimated Growth
Estimates Accuracy
-66%
Average Miss

Over the last 7 years, the compound annual growth rate for Net Income has been -8%. The projected CAGR for the next 3 years is 64%.

What are analyst estimates?

Continue RPRX Research

Summary
RPRX intrinsic value, competitors valuation, and company profile.
DCF Valuation
RPRX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RPRX stock valuation using valuation multiples.
Wall St Estimates
RPRX price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RPRX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Royalty Pharma PLC listings:
F • EUR
RPD
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is RPRX's stock price target?
Price Target
66.81 USD

According to Wall Street analysts, the average 1-year price target for RPRX is 66.81 USD with a low forecast of 46.46 USD and a high forecast of 73.5 USD.

What is the Revenue forecast for Royalty Pharma PLC?
Projected CAGR
18%

Over the last 7 years, the compound annual growth rate for Revenue has been 4%. The projected CAGR for the next 3 years is 18%.

What is the Operating Income forecast for Royalty Pharma PLC?
Projected CAGR
12%

Over the last 7 years, the compound annual growth rate for Operating Income has been 2%. The projected CAGR for the next 8 years is 12%.

What is the Pre-Tax Income forecast for Royalty Pharma PLC?
Projected CAGR
38%

Over the last 7 years, the compound annual growth rate for Pre-Tax Income has been -2%. The projected CAGR for the next 3 years is 38%.

What is the Net Income forecast for Royalty Pharma PLC?
Projected CAGR
64%

Over the last 7 years, the compound annual growth rate for Net Income has been -8%. The projected CAGR for the next 3 years is 64%.

Back to Top
ALPHA SPREAD
Follow us
Join 359,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.